Resonance Health China Roadshow - March 2026

Resonance Health explores China market opportunities — five days - four cities. 

We are excited to share highlights from our Hong Kong & China Roadshow during March, where our team — Andrew Harrison (MD & CEO), Dr Wenjie Pang (CSO) and Ben Carruthers (CFO)— explored commercial opportunities for our non-invasive MRI imaging products across the region. 

Our LiverSmart® AI-powered multi-parametric MRI solution — which measures liver iron and liver fat in a single scan — generated strong interest at every stop, particularly within China's rapidly expanding medical tourism and high-end health check sectors. 

Shulan (Boao) Hospital — Hainan 

Oasis International Hospital, Beijing 

 Dr Wenjie Pang & Ben Carruthers at Oasis, Beijing 

Key highlights from the trip: 

🏛️ Boao Lecheng International Medical Tourism Pilot Zone — Administration 

Deputy Director Ms Fu Zhu confirmed that LiverSmart® "meets conditions for introduction" under Lecheng's licensed product policy — which grants access to innovative devices approved in other countries before Chinese NMPA registration, with priority real-world data pathways to full approval. 

🏥 Shulan (Boao) Hospital  

One of Lecheng's largest specialist hospitals. Their team confirmed strong alignment with LiverSmart® — and agreed in principle to the product "landing in the hospital", with detailed technical and pricing discussions underway. Shulan medical group has over 7,000 private hospital beds across China. 

🌿 Boao Yiling Life Care Centre 

A premium international medical tourism destination with 500,000 members across 6 major campuses. Their team confirmed LiverSmart® aligns with their non-invasive testing philosophy and could be included in their VIP Health Check Package. 

🔬 International Innovative Pharmaceuticals & Devices Product Promotion Conference 

Dr Pang was invited to present at the Lecheng Administration's official Product Promotion Conference — attended by Hainan government health leaders.  

 Dr Wenjie Pang presenting RHT's products — Lecheng International Innovative Pharmaceuticals & Devices Conference, 25 March 2026 

🏙️ Oasis International Hospital — Beijing 

Oasis is a well respected high-end hospital in Beijing — a BOE Technology Group subsidiary with hospitals across Beijing, Chengdu, Suzhou, and Hefei. Strong interest from their international patient services team, with further introductions to major Beijing clinic and hospital networks offered.

 🤝 OT&P Healthcare — Hong Kong 

Hong Kong's only ACHS-accredited clinic group, with 90 practitioners across 8 premium clinics and a growing Wellness & Functional Medicine division — highly complementary to RHT's metabolic health products. 

Photo highlights 

Boao Yiling Life Care Centre — Hainan 

Yiling Hospital Management Group facility 

The China market opportunity for non-invasive liver assessment is significant — particularly within Lecheng's unique regulatory framework, which enables real-world data collected in the pilot zone to accelerate full NMPA registration in mainland China. 24 products have already obtained Chinese Import Registration Licenses through this pathway. 

Next steps include finalising Memoranda of Understanding with key Lecheng partners, completing the product information submission for pre-approval, and planning a follow-up roadshow to advance these discussions. 

We thank all the organisations who gave their time and welcomed us so warmly across Hong Kong, Hainan, Shanghai, and Beijing. 🙏